| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/20/2006 | CA2379585C Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| 06/20/2006 | CA2354770C Compositions with enhanced photoprotective effect and method for using same |
| 06/20/2006 | CA2285012C Remedy for external application, and use of an oil-in-water emulsion for said remedy |
| 06/20/2006 | CA2263404C Pharmaceutical composition comprising coenzyme q10 |
| 06/20/2006 | CA2260423C Pharmaceutical composition of hedgehog proteins and use thereof |
| 06/20/2006 | CA2246657C Inhibition of protein glycation and prevention of vasculopathy |
| 06/20/2006 | CA2235017C 4a,5a,8a,8b-tetrahydro-6h-pyrrolo[3,4':4,5]furo(3,2-b)pyridine-6,8[7h]-dione derivatives for use in controlling endoparasites and a method of producing said derivatives |
| 06/20/2006 | CA2220103C Composition comprising amoxycillin and clavulanic acid |
| 06/20/2006 | CA2177392C Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| 06/20/2006 | CA2176144C Anthracycline derivatives for treatment of amyloidosis |
| 06/20/2006 | CA2173553C Dextrin ester of fatty acids and use thereof |
| 06/20/2006 | CA2162706C 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease |
| 06/20/2006 | CA2142204C A vitamin d derivative with substituent at the 2.beta.-position |
| 06/20/2006 | CA2135480C Trisubstituted phenyl derivatives as phosphodiesterase inhibitors and processes for their preparation |
| 06/20/2006 | CA2121523C Sulfonamide derivatives |
| 06/17/2006 | CA2585798A1 Process for the control of production of fine chemicals |
| 06/17/2006 | CA2490484A1 Treatment of obstructive sleep apnea |
| 06/16/2006 | WO2006063430A1 Multi-layer drug delivery device and method of manufacturing same |
| 06/15/2006 | WO2006063350A2 Compositions and methods for treating conditions of the nail unit |
| 06/15/2006 | WO2006063294A2 Novel inhibitors of histone deacetylase for the treatment of disease |
| 06/15/2006 | WO2006063293A2 THIOUREAS AS FACTOR Xa INHIBITORS |
| 06/15/2006 | WO2006063281A2 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
| 06/15/2006 | WO2006063256A2 Treatment using d-threo methylphenidate |
| 06/15/2006 | WO2006063179A1 12-aryl prostaglandin analogs |
| 06/15/2006 | WO2006063178A2 Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof |
| 06/15/2006 | WO2006063175A2 Taurine-based compositions, therapeutic methods, and assays |
| 06/15/2006 | WO2006063167A1 1h-pyrrolo[2,3-b]pyridines |
| 06/15/2006 | WO2006063164A2 Compositions and methods for treating neuroendocrine tumors |
| 06/15/2006 | WO2006063154A1 Composition for proteasome inhibition |
| 06/15/2006 | WO2006063149A1 Nucleosides with antiviral and anticancer activity |
| 06/15/2006 | WO2006063135A2 Tubulin isotype screnning in cancer therapy using hemiasterlin analogs |
| 06/15/2006 | WO2006063128A2 Methods, assays and compositions for treating retinol-related diseases |
| 06/15/2006 | WO2006063113A2 Ureas as factor xa inhibitors |
| 06/15/2006 | WO2006063111A2 Pharmaceutical formulations cytidine analogs and derivatives |
| 06/15/2006 | WO2006063109A2 Room-temperature stable dronabinol formulations |
| 06/15/2006 | WO2006063091A2 Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity |
| 06/15/2006 | WO2006063078A2 Topiramate pharmaceuticals composition |
| 06/15/2006 | WO2006063058A2 Small molecule inhibitors of bacterial dam dna methyl transferases |
| 06/15/2006 | WO2006063039A2 3, 6-bicyclolides |
| 06/15/2006 | WO2006063033A2 Aryl amide sphingosine 1-phosphate analogs |
| 06/15/2006 | WO2006063025A1 Stable non-crystalline formulation comprising donepezil |
| 06/15/2006 | WO2006063010A2 Compounds and methods of use thereof |
| 06/15/2006 | WO2006062980A2 Stable non-crystalline formulation comprising tiagabine |
| 06/15/2006 | WO2006062938A2 Weight reduction and maintenance method for animals |
| 06/15/2006 | WO2006062933A2 Stable compositions of fenofibrate with fatty acid esters |
| 06/15/2006 | WO2006062932A2 Treatment with omega-3 fatty acids and ppar agonist and/or antagonist and a combination product thereof |
| 06/15/2006 | WO2006062931A2 Medical combinations |
| 06/15/2006 | WO2006062901A2 Silacycle compounds and methods of use thereof |
| 06/15/2006 | WO2006062898A2 Compounds and methods for treating hemorrhagic fever viruses |
| 06/15/2006 | WO2006062883A2 Medical combinations |
| 06/15/2006 | WO2006062875A1 Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
| 06/15/2006 | WO2006062855A2 Compositions and methods based upon the kinase haspin |
| 06/15/2006 | WO2006062839A1 Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
| 06/15/2006 | WO2006062748A2 Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
| 06/15/2006 | WO2006062731A1 Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye |
| 06/15/2006 | WO2006062723A2 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| 06/15/2006 | WO2006062683A2 Treatment and prevention of epilepsy |
| 06/15/2006 | WO2006062681A1 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 06/15/2006 | WO2006062658A1 Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4] triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| 06/15/2006 | WO2006062655A2 Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4] triazol-1-yl}-1h-pyrrolo[2,3-c]pyridin-3-yl}-ethane-1,2-dione |
| 06/15/2006 | WO2006062581A2 Delivery of therapeutic rnai agents for treating restenosis |
| 06/15/2006 | WO2006062580A1 Indane amides with antiproliferative activity |
| 06/15/2006 | WO2006062481A1 New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
| 06/15/2006 | WO2006062478A1 Novel treatment of gastrointestinal disorders |
| 06/15/2006 | WO2006062465A1 Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy |
| 06/15/2006 | WO2006062434A1 Modified 5'- phosphonate azidothymidine-potential anti-viral preparations |
| 06/15/2006 | WO2006062424A2 Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system |
| 06/15/2006 | WO2006062369A1 Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna |
| 06/15/2006 | WO2006062249A1 Substituted heterocyclic compound and thrombopoietin receptor activator |
| 06/15/2006 | WO2006062247A1 Substituted heterocyclic compound and thrombopoietin receptor activator |
| 06/15/2006 | WO2006062240A1 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
| 06/15/2006 | WO2006062238A1 Fine powder of amino acid and suspension thereof |
| 06/15/2006 | WO2006062233A1 A staining composition for staining an ophthalmic membrane |
| 06/15/2006 | WO2006062224A1 Carboxamide derivative |
| 06/15/2006 | WO2006062184A1 Product containing prostaglandin having fluorine atom in molecule |
| 06/15/2006 | WO2006062110A1 Piperazine derivative |
| 06/15/2006 | WO2006062097A1 Agent for prevention and/or treatment of pruritus |
| 06/15/2006 | WO2006062094A1 Novel cancer antigen peptide and the use thereof |
| 06/15/2006 | WO2006062093A1 Novel anthranilic acid derivative or salt thereof |
| 06/15/2006 | WO2006062072A1 Remedy for cancer metastasis and cancer metastasis inhibitor |
| 06/15/2006 | WO2006062069A1 REMEDY FOR PRURITUS COMPRISING p38MAP KINASE AS THE ACTIVE INGREDIENT |
| 06/15/2006 | WO2006062063A1 Piperidine derivative and process for producing the same |
| 06/15/2006 | WO2006061992A1 Preventive/therapeutic composition for liver disease |
| 06/15/2006 | WO2006061990A1 Liquid agent composition for contact lens |
| 06/15/2006 | WO2006061915A1 Skin remedy composition |
| 06/15/2006 | WO2006061791A2 Novel diazabicyclononene derivative |
| 06/15/2006 | WO2006061716A1 Pharmaceutical formulation comprising low crystallinity cellulose |
| 06/15/2006 | WO2006061715A2 Methylene inhibitors of matrix metalloproteinase |
| 06/15/2006 | WO2006061712A2 Use of mek inhibitors in treating abnormal cell growth |
| 06/15/2006 | WO2006061706A1 Tetrazolyl-methylene amino acid derivatives |
| 06/15/2006 | WO2006061697A1 Sulfonylurea compositions and a process for its preparation |
| 06/15/2006 | WO2006061689A1 Topical drug delivery system |
| 06/15/2006 | WO2006061685A1 A cost-effective process for preparation of manufacture of iron sucrose |
| 06/15/2006 | WO2006061683A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta |
| 06/15/2006 | WO2006061642A1 Compounds |
| 06/15/2006 | WO2006061624A1 Compositions for use in surgery |
| 06/15/2006 | WO2006061585A1 Pyrrolidine compounds |
| 06/15/2006 | WO2006061549A1 Process for the preparation of tamsulosin and intermediates thereof |
| 06/15/2006 | WO2006061525A2 Compositions for treating surface ocular pathologies |
| 06/15/2006 | WO2006061502A1 Tablets for the sustained release of indapamide and preparation method thereof |